Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Bone Marrow Transplantation|June 3, 2014
Extracorporeal photopheresis for treatment of adults and children with acute GVHD: UK consensus statement and review of published literatureE Das-Gupta, F Dignan, B Shaw, et al.
Bone Marrow Transplantation|April 14, 2015
Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCTC K Brierley, T J Littlewood, A J Peniket, et al.
Bone Marrow Transplantation|October 20, 2010
Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivationP Medd, S Littlewood, R Danby, et al.
Iscience|March 5, 2021
Lymphopenia-induced lymphoproliferation drives activation of naive T cells and expansion of regulatory populationsS Eldershaw, K Verma, W Croft, et al.
Iscience|February 26, 2025
Erratum: Lymphopenia-induced lymphoproliferation drives activation of naive T cells and expansion of regulatory populationsS Eldershaw, K Verma, W Croft, et al.
Bone Marrow Transplantation|October 14, 2014
A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequentJ J Scarisbrick, F L Dignan, S Tulpule, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2016
Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow TransplantationS Genadieva-Stavrik, A Boumendil, P Dreger, et al.
Leukemia Research|February 12, 2013
Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplantE Nikolousis, S Robinson, S Nagra, et al.
Bone Marrow Transplantation|December 1, 2015
Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working PartyS P Robinson, A Boumendil, H Finel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 24, 2019
Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)J R Passweg, M Labopin, M Christopeit, et al.
Pageof 4